1AI

0.00%

0.7¢ algorae pharmaceuticals limited

Completely agree Magilla.Hope your investments go as well as...

First 7 Last

Share
Profile

Follow
dsorg

864 Posts.

590

23/02/24

14:16

Post #: 72561691
Share

Originally posted by Magilla208: ↑

One of the things (amongst many) that has attracted me to this stock is the fact the directors are paying themselves low cash fees and are fully incentivized by their performance packages.

I think 3 cents is a fantastic milestone, that’s nearly triple the price from here for anyone who has just entered or anyone looking at buying a position unless of course you have paid much higher prices under the previous board of directors who failed to deliver shareholder value with the strategy that they adopted.

I hope they achieve all of their milestones because my position will certainly benefit financially if they do. I have done a lot of research into the fact that many believe that we are at a point where most of the drugs to be developed in the world have in fact been developed and that the future of being able to create drugs that can treat unaddressable indications lies with new drug combinations.

What 1AI have done here in partnering up with the UNSW is extremely smart and allows them access to the most advanced AI platform in this space. The potential for AI to assist with combination drug development cannot be understated in my view. The UNSW team are the real deal, just look at Professor Fatemeh Vafee as the leader of the project - she is educated in the US and has a PHD in Artificial Intelligence form the School of Computer Science at the University of Illinois and has been recoginsed internationally by her peers, not to mention (and I quote form the announcement made on the 11th September) she has already had a “decade of experience in AI-integrated transitional medicine and drug discovery through close partnerships with industry and governmental stakeholder.”

This truly is an exciting venture and I for one am more than happy to bet on the leverage from this current valuation of 1AI. Most stocks in this space in the US are all trading with $1billion market caps. Now I’m not for one moment suggesting that should be the case with 1AI but what I am saying is this valuation of $19m AUD is way under for where the company is at in my opinion anyway. As usual we are trailing the US in terms of valuations but I’m hoping that the investment community in Australia will wake up to this as we only need one successful drug combination to knock it out of the park form here and i think the risk/reward equation from her is compell

Expand

Completely agree Magilla.

Hope your investments go as well as your reasoning. News flow seems to be close.

I also like the concept of NT Cell working in tandem with DBS. Brain surgery is pretty invasive, so if they can piggyback each other then that would be really powerful for us trying to reduce our Parkinson’s symptoms (of which I am one).

Cheers

Last edited by dsorg: 23/02/24

1AI Price at posting: 1.2¢ Sentiment: Buy Disclosure: Held
1 Upvote

0 Great analysis

Reply

Top Stories

DEG

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

ZER

Zeta Resources seeks to resolve the Panoramic takeover story

STK

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

NAM

ACCC seeks Olam divestments before its acquisition of Namoi Cotton can go ahead

The winners & losers on market if negative gearing were gone

4DX

4DMedical lands Philips US reseller deal with eye to Veterans Affairs' market post-lung damage

ESR

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

The market's shrugged at China's stimulus measures all year. Why is this one different?

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

There are more pages in this discussion • 2 more messages in this thread...

First 7 Last

Add 1AI (ASX) to my watchlist

(20min delay)
Last 0.7¢		Change 0.000(0.00%)		Mkt cap ! $11.81M

Open	High	Low	Value	Volume
0.7¢	0.7¢	0.6¢	$41.21K	6.825M

Buyers (Bids)

No.	Vol.	Price($)
7	3056700	0.6¢

Sellers (Offers)

Price($)	Vol.	No.
0.7¢	913000	5

View Market Depth

No.	Vol.	Price($)
7	3056700	0.006
11	5611786	0.005
7	5195009	0.004
2	3100000	0.003
2	1050000	0.002

Price($)	Vol.	No.
0.007	913000	5
0.008	1125668	9
0.009	2425910	11
0.010	4020149	6
0.011	1490400	3

Last trade - 15.36pm 27/09/2024 (20 minute delay)

1AI (ASX) Chart

Completely agree Magilla.Hope your investments go as well as...

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

Zeta Resources seeks to resolve the Panoramic takeover story

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

ACCC seeks Olam divestments before its acquisition of Namoi Cotton can go ahead

The winners & losers on market if negative gearing were gone

4DMedical lands Philips US reseller deal with eye to Veterans Affairs' market post-lung damage

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

The market's shrugged at China's stimulus measures all year. Why is this one different?

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Completely agree Magilla.Hope your investments go as well as...

Top Stories

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

Zeta Resources seeks to resolve the Panoramic takeover story

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

ACCC seeks Olam divestments before its acquisition of Namoi Cotton can go ahead

The winners & losers on market if negative gearing were gone

4DMedical lands Philips US reseller deal with eye to Veterans Affairs' market post-lung damage

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

The market's shrugged at China's stimulus measures all year. Why is this one different?

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News